NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. The company operates through its wholly-owned subsidiary NeuroRx,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NRX Pharmaceuticals, Inc. does
In the company’s own words
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. The company operates through its wholly-owned subsidiary NeuroRx, Inc., and is the majority owner of HOPE Therapeutics, Inc., a medical services organization providing interventional psychiatry care.
The company's drug development pipeline focuses on therapies that enhance neuroplasticity by modulating the N-methyl-D-aspartate receptor. NRx's three lead drug candidates are NRX-100, a preservative-free ketamine formulation for intravenous infusion; KETAFREE, a generic preservative-free ketamine formulation; and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. KETAFREE has an Abbreviated New Drug Application pending with the FDA, with anticipated approval in Q3 2026. NRX-100 has received Fast Track Designation for treatment of suicidal ideation in depression and a New Drug Application filing is expected in Q2 2026. NRX-101, which received Breakthrough Therapy Designation, has an NDA filing underway with accelerated approval sought for treating suicidal bipolar depression with akathisia.
HOPE Therapeutics operates clinical facilities offering ketamine infusion therapy, transcranial magnetic stimulation, digital therapeutics, and hyperbaric therapy. The subsidiary generated its first clinical revenue in Q4 2025 and currently operates five locations in Florida with expansion planned to eight or more locations by mid-2026. HOPE completed acquisitions of Dura Medical and a minority interest in Cohen and Associates during 2025.
The company maintains a patent portfolio licensed from Glytech and SHMH, along with NeuroRx-owned patents covering compositions of matter and methods of use. Manufacturing agreements with Alcami and Nephron Pharmaceuticals support production of NRX-101 and ketamine formulations domestically. As of December 31, 2025, NRx employed approximately 29 full-time employees. The current generic ketamine market exceeds $750 million annually, while the market for ketamine-based depression treatments is served primarily by a nasal S-ketamine preparation with estimated annual sales around $2 billion.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 1719406
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NRX Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NRX Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NRX Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NRX Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NRX Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”